Drug Report History #146183
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v4-EN | Version v1-EN |
|---|---|---|
| Language | English | English |
| Date Updated | 2021-10-09 (Updated) | 2021-09-24 |
| Drug Identification Number | 02426269 | 02426269 |
| Brand name | ATROPINE SULFATE INJECTION | ATROPINE SULFATE INJECTION |
| Common or Proper name | Atropine Sulfate Injection | Atropine Sulfate Injection |
| Company Name | BIOSYENT PHARMA INC | BIOSYENT PHARMA INC |
| Ingredients | ATROPINE SULFATE | ATROPINE SULFATE |
| Strength(s) | 0.5MG | 0.5MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 0.5 mg/5mL pre-filled syringe. 10 syringes per carton. | 0.5 mg/5mL pre-filled syringe. 10 syringes per carton. |
| ATC code | A03BA | A03BA |
| ATC description | BELLADONNAAND DERIVATIVES, PLAIN | BELLADONNAAND DERIVATIVES, PLAIN |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2021-10-08 | 2021-10-08 |
| Actual start date | ||
| Estimated end date | 2021-10-22 | 2021-10-22 |
| Actual end date | ||
| Shortage status | Actual shortage (Updated) | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Unanticipated heavy demand increase for drug. | Unanticipated heavy demand increase for drug. |
| Health Canada comments |